Organ and tumour dosimetry of ¹⁷⁷Lu-rhPSMA-10.1, a novel PSMA-targeted therapy: results from a Phase I trial

Keyphrases

• Tumor 100%
• Targeted Therapy 100%
• Lutetium-177 (177Lu) 100%
• Phase I Trial 100%
• Tumor Dosimetry 100%
• Organ Dosimetry 100%
• Kidney 50%
• Tumor Absorbed Dose 50%
• Radioactivity 33%
• Salivary Gland 33%
• Activity Method 33%
• Effective Half-life 33%
• SPECT-CT 16%
• Disease Progression 16%
• Clinical Trials 16%
• Pharmacokinetics 16%
• Imaging Data 16%
• Venous Blood 16%
• Dosimetry 16%
• High-dose Radiation 16%
• Absorbed Dose 16%
• Cumulative Dose 16%
• Salivary Gland Tumor 16%
• Tumor Activity 16%
• Metastatic Castration-resistant Prostate Cancer (mCRPC) 16%
• 3-cycle 16%
• Dose Estimates 16%
• Treatment Standards 16%
• Organ Absorbed Dose 16%
• Multi-bed 16%
• Front-loading 16%
• Radioactivity Measurement 16%
• Tolerable Limit 16%

Medicine and Dentistry

• Targeted Therapy 100%
• Tumor 100%
• Dosimetry 100%
• Lutetium 177 100%
• Phase I Trials 100%
• Absorbed Dose 36%
• Salivary Gland 18%
• Single Photon Emission Computed Tomography-Computed Tomography 9%
• Clinical Trial 9%
• Disease Exacerbation 9%
• Kidney Tumour 9%
• Venous Blood 9%
• Pharmacokinetics 9%

Pharmacology, Toxicology and Pharmaceutical Science

• Dosimetry 100%
• Phase I Trials 100%
• Lutetium 177 100%
• Effective Half-Life 33%
• Clinical Trial 16%
• Disease Exacerbation 16%
• Kidney Tumour 16%
• Salivary Gland Tumor 16%
• Pharmacokinetics 16%